

**Table 3** Estimated vaccine efficacy used for the TRIVAC model to estimate the health impact of PCV-13

Variable	Estimate (%)	Scenario		Source/s
		High	Low	
<b><i>Vaccine efficacy for all-cause acute otitis media</i></b>				
Dose 1	28.9	48.4	25.3	Mahon et al. 2006 (24)
Dose 2	52.5	63.0	46.0	Mahon et al. 2006 (24)
Dose 3	57.0	63.0	50.0	Pavia et al. 2009 (24)
<b><i>Vaccine efficacy for vaccine-type pneumococcal pneumonia/meningitis/NPNM</i></b>				
Dose 1	41.0	69.2	31.9	Mahon et al. 2006 (24)
Dose 2	74.5	90.0	58.0	Mahon et al. 2006 (24)
Dose 3	81.0	90.0	63.0	Lucero et al. 2015 (2)
<b><i>Vaccine serotype coverage</i></b>				
Acute otitis media	70.0	64.0	75.0	Johnson et al. 2010 (25)
Pneumococcal pneumonia	70.0	64.0	75.0	Johnson et al. 2010 (25)
Pneumococcal meningitis	70.0	64.0	75.0	Johnson et al. 2010 (25)
Pneumococcal NPNM	70.0	64.0	75.0	Johnson et al. 2010 (25)
<b><i>Other assumptions for vaccination impact</i></b>				
Relative coverage	90.0	80.0	100.0	TRIVAC assumption (15)
Decrease in dose efficacy per year	5.0	0.0	10.0	TRIVAC assumption (15)
Contribution of herd effect in children < 5 years	110.0	100.0	120.0	TRIVAC assumption (15)
Decline in vaccine-type coverage per year	5.5	0.0	5.0	TRIVAC assumption (15)

PCV = pneumococcal conjugate vaccine; NPNM = non-pneumonia, non-meningitis, and other diseases except sepsis.